Skip to main content
Clinical Trials/NL-OMON38302
NL-OMON38302
Recruiting
Not Applicable

Blood-brain barrier permeability and cerebral perfusion in Alzheimer*s disease - Vascular dysfunction in AD

niversiteit Maastricht0 sites60 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
neurodegeneratieve aandoeningen
Sponsor
niversiteit Maastricht
Enrollment
60
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with AD:
  • Informed consent before participation in the study
  • Received standard diagnostic procedure according to the Parelsnoer Initiative procedure
  • Diagnosed with dementia of the Alzheimer\*s type
  • Clinical dementia rating (CDR) of 1, which means a mild to moderate stage of dementia
  • MMSE \>\= 20 and patients are mentally competent This inclusion criterion is conform the Parelsnoer Initiative inclusion criteria. By the Parelsnoer Initiative, individuals with an MMSE \>\=18 are considered mentally competent.;Patients with prodromal AD:
  • Informed consent before participation in the study
  • Received standard diagnostic procedure according to the Parelsnoer Initiative procedure
  • Diagnosis of prodromal dementia according to the Dubois criteria (16\)
  • CDR of 0\.5, which suggests a very mild stage of dementia

Exclusion Criteria

  • Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, large body tattoos)
  • Contraindications for contrast agent Gadovist (renal failure) as determined by the estimated Glomular Filtration Rate eGFR \< 30 mL/min.
  • Major vascular disorders (e.g. stroke, heart disease)
  • Psychiatric or neurological disorders (e.g. Major depression; history of schizophrenia; bipolar disorder; psychotic disorder NOS or treatment for a psychotic disorder; cognive impairment due to alcohol abuse; epilepsy, Parkinson\*s disease, MS, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Meniere\*s disease, brain infections)
  • Structural abnormalities of the brain
  • Cognitive impairment due to alcohol/drug abuse
  • Absence of reliable informant (for AD patient groups)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Quantitative blood-brain barrier permeability and susceptibility mapping for patients with CADASIL and suspected to have CADASICADASI
JPRN-UMIN000035081agoya City University40
Active, not recruiting
Not Applicable
Permeability of the blood-brain barrier in Alzheimer’s disease
ISRCTN17419165niversity of Southampton70
Recruiting
Not Applicable
Blood brain barrier permeability and inflammatory biomarkers in patients with depressioF32.2F32.3F33.2F33.3Severe depressive episode without psychotic symptomsSevere depressive episode with psychotic symptomsRecurrent depressive disorder, current episode severe without psychotic symptomsRecurrent depressive disorder, current episode severe with psychotic symptoms
DRKS00022091Klinik für Psychiatrie, Psychosomatik und PsychotherapieUniversitätsklinikum Frankfurt100
Active, not recruiting
Not Applicable
Studies on Permeability of the Blood-Brain-Barrier for Escitaloprame related to various Genotypes of the ABCB1-Gene: Effects on Sleep and Motoric Learning - Escitaloprame, sleep, blood-brain-barrierEffects on sleep electroencephalogram and motoric learning in healthy volunteers related to the permeability of the blood-brain-barrier related to genotypes of the ABCB 1 gene
EUCTR2006-001491-21-DEMax Planck Institute of Psychiatry58
Completed
Not Applicable
Blood-Brain Barrier permeability quantification in cerebral small vessel disease -- reproducibility of dynamic contrast-enhanced MRICerebral small vessel diseasedisease of the small brain arteries10007963
NL-OMON38519Medisch Universitair Ziekenhuis Maastricht20